Our Vision: “Every drug can be made and every disease can be treated” by building an open-access platform with the most comprehensive capabilities and technologies in the global biologics industry. Our Mission: To accelerate and transform the discovery, development and manufacturing of biologics through a comprehensive open-access platform, enabling our global healthcare partners and benefiting patients worldwide. Our Company: WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly ONE-stop service offering and strong value proposition to its global clients. With total estimated capacity for biopharmaceutical production planned in the U.S., China, Ireland, Germany, and Singapore exceeding 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
View Top Employees from WuXi BiologicsWebsite | https://www.wuxibiologics.com/ |
Ticker | HKG:2269 |
Revenue | $560 million |
Employees | 2,815 (1,961 on RocketReach) |
Founded | 2010 |
Address | Meiliang Mashan Binhu District Rd No 108, Wuxi 214092, CN |
Phone | +86 510 8183 1205 |
Technologies |
JavaScript,
HTML,
PHP
+39 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Manufacturing General, Health Care, Biologics conjugation, Manufacturing, Pharmaceutical, Bioprocess CMC, Biosafety, Biologics GMP Manufacturing, Biologics discovery service, Cell Line Development, Formulation Development, Analytical Characterization, Cell Culture and Purification Process Development, Monoclonal Antibodies (mAbs) |
Keywords | Contract Development And Manufacturing, Biopharmaceuticals |
Competitors | Catalent Pharma Solutions, FUJIFILM Diosynth Biotechnologies, KBI Biopharma, Samsung Biologics, Unither Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular WuXi Biologics employee's phone or email?
The WuXi Biologics annual revenue was $560 million in 2024.
Weichang Zhou is the Executive Vice President, Biologics Development and Manufacturing, and Chief Technology Officer of WuXi Biologics.
1,961 people are employed at WuXi Biologics.
The NAICS codes for WuXi Biologics are [3254, 32, 32541, 325].
The SIC codes for WuXi Biologics are [28, 283].